首页 > 市场调查报告书 > 製药

疼痛

市场调查报告书

商品编码

1604159

全球急性偏头痛治疗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Acute Migraine Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年11月01日 | 出版商:

Value Market Research | 英文 170 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球急性偏头痛治疗市场需求预计将从 2023 年的 33.6 亿美元达到近 124.6 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 15.69%。

偏头痛是一种反覆发作的神经系统疾病，会导致中度至剧烈头痛，通常伴随与自主神经系统相关的症状。急性偏头痛治疗是控制偏头痛症状的过程。急性偏头痛治疗的主要目标是尽快停止偏头痛并减轻相关症状。有多种药物可用于此目的，包括非处方药 (OTC) 和处方药。

市场动态

偏头痛（一种慢性神经系统疾病）的盛行率不断上升，推动了急性偏头痛治疗市场的发展。此外，随着越来越多的人寻求偏头痛治疗，人们越来越意识到偏头痛是一种合法的健康状况，这也推动了市场的发展。偏头痛有效治疗方法的不断增加预计将推动急性偏头痛治疗市场的成长。对更个人化的治疗方案的需求不断增长，也推动了新的、更有效的偏头痛治疗方法的发展。然而，高昂的治疗成本可能会阻碍市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球急性偏头痛治疗市场的每个细分市场进行了包容性评估。急性偏头痛治疗产业的成长和趋势为本研究提供了整体方法。

市场区隔

急性偏头痛治疗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

依药物类型

曲普坦类
CGRP拮抗剂
非类固醇抗发炎药
β-肾上腺素阻断剂
麦角生物碱
其他的

依给药途径

口服
注射
其他的

按配销通路

医院药房
零售药局
网路药局

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的急性偏头痛治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。急性偏头痛治疗市场的主要参与者包括梯瓦製药、罗氏有限公司、强生公司、安进公司、阿斯特捷利康公司、辉瑞公司、默克公司、诺华公司、艾尔建公司、礼来公司、BioDelivery Sciences国际公司，艾伯维。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：急性偏头痛治疗公司的竞争格局

急性偏头痛治疗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
Teva Pharmaceutical

公司概况
公司收入
产品
最新动态

Hoffmann-La Roche Ltd.

公司概况
公司收入
产品
最新动态

Johnson & Johnson

公司概况
公司收入
产品
最新动态

Amgen

公司概况
公司收入
产品
最新动态

AstraZeneca

公司概况
公司收入
产品
最新动态

Pfizer Inc.

公司概况
公司收入
产品
最新动态

Merck & Co.

公司概况
公司收入
产品
最新动态

Novartis AG

公司概况
公司收入
产品
最新动态

Allergan Plc

公司概况
公司收入
产品
最新动态

Eli Lilly And Company

公司概况
公司收入
产品
最新动态

BioDelivery Sciences International Inc.

公司概况
公司收入
产品
最新动态

AbbVie

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112110233

The global demand for Acute Migraine Treatment Market is presumed to reach the market size of nearly USD 12.46 Billion by 2032 from USD 3.36 Billion in 2023 with a CAGR of 15.69% under the study period 2024-2032.

Migraine is a recurring neurological condition that causes moderate to intense headaches, often accompanied by symptoms related to the autonomic nervous system. Acute migraine treatment is the process of managing the symptoms of a migraine headache. The primary goal of acute migraine treatment is to stop the migraine headache as soon as possible and to alleviate the associated symptoms. There are several medications that can be used for this purpose, including over-the-counter (OTC) medications and prescription medications.

MARKET DYNAMICS

The increasing prevalence of migraines, a chronic neurological disorder, drives the market for acute migraine treatment. Moreover, the growing awareness of migraines as a legitimate health condition is also driving the market as more people seek treatment for them. The growing availability of effective treatments for migraines is expected to boost the acute migraine treatment market growth. The development of new and more effective migraine treatments is also driven by the increasing demand for more personalized treatment options. However, the high cost of treatment may impede the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Acute Migraine Treatment. The growth and trends of Acute Migraine Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Acute Migraine Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Triptans
CGRP Antagonist
NSAID Drugs
Beta-adrenergic Blockers
Ergot Alkaloids
Others

By Route of Administration

Oral
Injection
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Acute Migraine Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acute Migraine Treatment market include Teva Pharmaceutical, Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen, AstraZeneca, Pfizer Inc., Merck & Co., Novartis AG, Allergan Plc, Eli Lilly And Company, BioDelivery Sciences International Inc., AbbVie. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ACUTE MIGRAINE TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ACUTE MIGRAINE TREATMENT MARKET ANALYSIS BY DRUG TYPE

5.1. Overview By Drug Type
5.2. Historical and Forecast Data Analysis By Drug Type
5.3. Triptans Historic and Forecast Sales By Regions
5.4. CGRP Antagonist Historic and Forecast Sales By Regions
5.5. NSAID Drugs Historic and Forecast Sales By Regions
5.6. Beta-adrenergic Blockers Historic and Forecast Sales By Regions
5.7. Ergot Alkaloids Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL ACUTE MIGRAINE TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Oral Historic and Forecast Sales By Regions
6.4. Injection Historic and Forecast Sales By Regions
6.5. Others Historic and Forecast Sales By Regions

7. GLOBAL ACUTE MIGRAINE TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data Analysis By Distribution Channel
7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
7.4. Retail Pharmacies Historic and Forecast Sales By Regions
7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL ACUTE MIGRAINE TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ACUTE MIGRAINE TREATMENT COMPANIES

9.1. Acute Migraine Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF ACUTE MIGRAINE TREATMENT INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Teva Pharmaceutical
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Hoffmann-La Roche Ltd.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Johnson & Johnson
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Amgen
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. AstraZeneca
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Pfizer Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Merck & Co.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Novartis AG
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Allergan Plc
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Eli Lilly And Company
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. BioDelivery Sciences International Inc.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. AbbVie
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments